Hachimijiogan Changes Serum Hormonal Circumstance and Improves Spermatogenesis in Oligozoospermic Men

1986 ◽  
Vol 14 (01n02) ◽  
pp. 37-45 ◽  
Author(s):  
S. Usuki
Keyword(s):  
Sperm Motility ◽  
Moderate Increase ◽  
Serum Estradiol ◽  
Remarkable Increase ◽  
Testosterone Levels ◽  
Fertility Index ◽  
Significant Change ◽  
Estradiol 17Β

28 men with oligozoospermia and 7 with azoospermia received 7.5 g of Hachimijiogan, daily for 8 to 28 weeks. Examinations of semen in oligozoospermic men after treatment revealed a remarkable increase in number (78%) and moderate increase in sperm motility (53%) and in volume (56%), and fertility index was also remarkably improved, whereas no improvement was found in azoospermic men. Furthermore, serum estradiol-17β level was significantly increased (P<0.005) after treatment, while LH, FSH, prolactin and testosterone levels in sera showed no significant change. These results suggest that Hachimijiogan increases serum estradiol-17 β levels and improves spermatogenesis in oligozoospermic men.

Potential anti-toxic effect of d-ribose-l-cysteine supplement on the reproductive functions of male rats administered cyclophosphamide

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Gabriel O. Oludare ◽  
Gbenga O. Afolayan ◽  
Ganbotei G. Semidara
Keyword(s):  
Body Weight ◽  
Single Dose ◽  
Sperm Motility ◽  
Sperm Count ◽  
Male Rats ◽  
Oxidative Enzymes ◽  
Protective Effects ◽  
Testosterone Levels ◽  
Group I ◽  
Antioxidant Defence System

Abstract Objectives This study aimed to access the protective effects of d-ribose-l-cysteine (DRLC) on cyclophosphamide (CPA) induced gonadal toxicity in male rats. Methods Forty-eight male Sprague-Dawley rats were divided into six groups of eight rats each. Group I the control, received distilled water (10 ml/kg), Group II received a single dose of CPA 100 mg/kg body weight intraperitoneally (i.p), Groups III and IV received a single dose of CPA at 100 mg/kg (i.p) and then were treated with DRLC at 200 mg/kg bodyweight (b.w) and 400 mg/kg b.w for 10 days, respectively. Rats in Groups V and VI received DRLC at 200 and 400 mg/kg b.w for 10 days, respectively. DRLC was administered orally. Results Results showed that CPA increased percentage of abnormal sperm cells and reduced body weight, sperm count, sperm motility, follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone levels (p<0.05). CPA also induced oxidative stress as indicated by the increased malondialdehyde (MDA) content and reduced activities of the oxidative enzymes measured (p<0.05). Liver enzymes were elevated while the blood cells production was decreased in the rats administered CPA. DRLC supplementation enhanced the antioxidant defence system as indicated in the reduced MDA levels and increased activities of the antioxidant enzymes when compared with CPA (p<0.05). Bodyweight, sperm count, sperm motility, FSH, and testosterone levels were increased in the CPA + DRLC II group compared with CPA (p<0.05). Conclusions The results of this present study showed that DRLC has a potential protective effect on CPA-induced gonadotoxicity.

scholarly journals Effects of coated and noncoated steroidal implants on growth performance, carcass characteristics, and serum estradiol-17β concentrations of finishing Holstein steers

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Pedro H V Carvalho ◽  
Mariana F Westphalen ◽  
Jonathan A Campbell ◽  
Tara L Felix
Keyword(s):  
Growth Performance ◽  
Animal Health ◽  
Average Daily Gain ◽  
Carcass Characteristics ◽  
Feed Ratio ◽  
Serum Estradiol ◽  
Trenbolone Acetate ◽  
Coated Implant ◽  
Daily Gain ◽  
Estradiol 17Β

Abstract The objectives of the study were to determine the effect of coated or noncoated hormone implants on growth performance, carcass characteristics, and serum estradiol-17β (E2) concentrations of Holstein steers fed a grain-based diet for 112 d. Seventy-nine Holstein steers [average initial body weight (BW) = 452 ± 5.5 kg] were stratified by BW and allotted to one of two treatments: 1) Holstein steers implanted with a coated implant containing 200 mg of trenbolone acetate (TBA) and 40 mg E2 (Revalor-XS (Merck Animal Health; Summit, NJ)] on day 0 (XS) or 2) Holstein steers implanted two times (days 0 and 56) with a noncoated implant containing 80 mg of TBA and 16 mg of E2 [(2IS) Revalor-IS (Merck Animal Health)]. Data were analyzed using the MIXED procedure of SAS (SAS Inst. Inc., Cary, NC). There was no effect (P ≥ 0.71) of implant strategy on initial, middle, and final BW. No effect (P ≥ 0.12) of implant strategy was observed on average daily gain, dry matter intake, or gain-to-feed ratio. There were no effects (P ≥ 0.11) of implant strategy on carcass characteristics. There was an implant × day interaction (P &lt; 0.01) for the circulation of serum E2 concentrations. Serum E2 concentration increased similarly 14 d after Holstein steers were implanted, regardless of implant strategy. At 28 d, after steers were implanted, steers in the XS group had less serum E2 concentration than Holstein steers in the 2IS group. However, at 56 d after the first implantation, both groups, once again, had similar serum E2 concentrations and E2 concentrations were less on day 56 than day 28 for both strategies. Holstein steers implanted with 2IS had greater serum E2 concentration on day 70 and E2 concentrations remained greater than serum E2 of Holstein steers implanted XS for the duration of the trial (day 112). In summary, there was no effect of coated or two doses of noncoated implant on growth performance or carcass characteristics of Holstein steers.

scholarly journals Efforts by Industry Toward Standardization of Serum Estradiol-17β Measurements

1998 ◽  
Vol 44 (3) ◽  
pp. 671-674 ◽  
Author(s):  
Linda M Thienpont ◽  
André P De Leenheer
Keyword(s):  
Serum Estradiol ◽  
Estradiol 17Β

Homozygous mutation of foxh1 arrests oogenesis causing infertility in female Nile tilapia†

2019 ◽  
Vol 102 (3) ◽  
pp. 758-769
Author(s):  
Wenjing Tao ◽  
Hongjuan Shi ◽  
Jing Yang ◽  
Hamidou Diakite ◽  
Thomas D Kocher ◽  
...  
Keyword(s):  
Phase Iii ◽  
Follicle Cells ◽  
Homozygous Mutation ◽  
Serum Estradiol ◽  
Oocyte Growth ◽  
Expression Of Genes ◽  
Estrogen Production ◽  
Estrogen Synthesis ◽  
Smad Protein ◽  
Estradiol 17Β

Abstract Foxh1, a member of fox gene family, was first characterized as a transcriptional partner in the formation of the Smad protein complex. Recent studies have shown foxh1 is highly expressed in the cytoplasm of oocytes in both tilapia and mouse. However, its function in oogenesis remains unexplored. In the present study, foxh1−/− tilapia was created by CRISPR/Cas9. At 180 dah (days after hatching), the foxh1−/− XX fish showed oogenesis arrest and a significantly lower GSI. The transition of oocytes from phase II to phase III and follicle cells from one to two layers was blocked, resulting in infertility of the mutant. Transcriptomic analysis revealed that expression of genes involved in estrogen synthesis and oocyte growth were altered in the foxh1−/− ovaries. Loss of foxh1 resulted in significantly decreased Cyp19a1a and increased Cyp11b2 expression, consistent with significantly lower concentrations of serum estradiol-17β (E2) and higher concentrations of 11-ketotestosterone (11-KT). Moreover, administration of E2 rescued the phenotypes of foxh1−/− XX fish, as indicated by the appearance of phase III and IV oocytes and absence of Cyp11b2 expression. Taken together, these results suggest that foxh1 functions in the oocytes to regulate oogenesis by promoting cyp19a1a expression, and therefore estrogen production. Disruption of foxh1 may block the estrogen synthesis and oocyte growth, leading to the arrest of oogenesis and thus infertility in tilapia.

Sign in / Sign up

Export Citation Format

Share Document